182 related articles for article (PubMed ID: 17166246)
1. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.
Hantgan RR; Stahle MC; Connor JH; Connor RF; Mousa SA
J Thromb Haemost; 2007 Mar; 5(3):542-50. PubMed ID: 17166246
[TBL] [Abstract][Full Text] [Related]
2. Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition.
Hantgan RR; Stahle MC
Biochemistry; 2009 Sep; 48(35):8355-65. PubMed ID: 19640007
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Wang X; Dorsam RT; Lauver A; Wang H; Barbera FA; Gibbs S; Varon D; Savion N; Friedman SM; Feuerstein GZ
J Pharmacol Exp Ther; 2002 Dec; 303(3):1114-20. PubMed ID: 12438534
[TBL] [Abstract][Full Text] [Related]
4. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Mousa SA; Bozarth JM; Forsythe MS; Slee A
Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
[TBL] [Abstract][Full Text] [Related]
5. RGD-ligand mimetic antagonists of integrin alphaIIbbeta3 paradoxically enhance GPVI-induced human platelet activation.
Jones ML; Harper MT; Aitken EW; Williams CM; Poole AW
J Thromb Haemost; 2010 Mar; 8(3):567-76. PubMed ID: 20002543
[TBL] [Abstract][Full Text] [Related]
6. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
Mousa SA; Bozarth JM; Naik UP; Slee A
Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Mousa SA; Abulencia JP; McCarty OJ; Turner NA; Konstantopoulos K
J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529
[TBL] [Abstract][Full Text] [Related]
8. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
9. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
10. Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
Schneider DJ; Baumann PQ; Whitaker DA; Sobel BE
J Cardiovasc Pharmacol; 2005 Jul; 46(1):41-5. PubMed ID: 15965353
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
Mousa SA; Khurana S; Forsythe MS
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
[TBL] [Abstract][Full Text] [Related]
12. Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.
Hantgan RR; Stahle MC; Jerome WG; Nagaswami C; Weisel JW
Thromb Haemost; 2002 May; 87(5):910-7. PubMed ID: 12038797
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
Hamilton SF; Miller MW; Thompson CA; Dale GL
J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
16. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
Giordano A; Musumeci G; D'Angelillo A; Rossini R; Zoccai GB; Messina S; Coscioni E; Romano S; Romano MF
Curr Drug Metab; 2016; 17(2):194-203. PubMed ID: 26652157
[TBL] [Abstract][Full Text] [Related]
17. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition.
Li YF; Spencer FA; Becker RC
Am Heart J; 2002 Apr; 143(4):725-32. PubMed ID: 11923812
[TBL] [Abstract][Full Text] [Related]
19. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
Schwarz M; Meade G; Stoll P; Ylanne J; Bassler N; Chen YC; Hagemeyer CE; Ahrens I; Moran N; Kenny D; Fitzgerald D; Bode C; Peter K
Circ Res; 2006 Jul; 99(1):25-33. PubMed ID: 16778135
[TBL] [Abstract][Full Text] [Related]
20. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
Billheimer JT; He B; Spitz SM; Stern AM; Seiffert D
Thromb Res; 2002 Sep; 107(6):303-17. PubMed ID: 12565717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
